Product
Supplier
Encyclopedia
Inquiry
Home > Pharmaceutical Intermediates > Bulk Drug Intermediates > Semaglutide for Sale > Retatrutide 99% Peptide Retatrutide5mg 10mg Vials
Retatrutide 99% Peptide Retatrutide5mg 10mg Vials buy - large image1
Retatrutide 99% Peptide Retatrutide5mg 10mg Vials buy - image1
Retatrutide 99% Peptide Retatrutide5mg 10mg Vials buy - image2
Retatrutide 99% Peptide Retatrutide5mg 10mg Vials buy - image3
Retatrutide 99% Peptide Retatrutide5mg 10mg Vials buy - image4
Retatrutide 99% Peptide Retatrutide5mg 10mg Vials buy - image5
Retatrutide 99% Peptide Retatrutide5mg 10mg Vials buy - image6

Retatrutide 99% Peptide Retatrutide5mg 10mg Vials

TDS 423 Inquiries

Unit Price:

$115-130/G FOB

Get Latest Price
CAS No.:

910463-68-2

Grade:

Pharmaceutical Grade

Content:

99%

Port:

suqain

Brand:

Horwats

Packaging:

10mg/package ,100mg/package

Sample Available:

Yes

Price valid (until):

2027-09-24

Company Type:
Trader
Location:
China
Qualification:
Main Products:

Vitamin K2,NAD+,Semaglutide,Tirzepatide,Sodium Glutathione

  • Product Details

  • Seller Information

  • Inquiry History

  • Description


      Product Detail  


    Retatrutide (LY3437943) acetate is a triple agonist peptide for the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide acetate inhibits human GCGR, GIPR, and GLP-1R with EC50 values of 5.79, 0.0643, and 0.775 nM, respectively. It exhibits activity on mouse GCGR, GIPR, and GLP-1R with EC50 values of 2.32, 0.191, and 0.794 nM, respectively. In vivo, Retatrutide (LY3437943) acetate engages with GCGR and enhances glucose tolerance in an ipGTT by acting through GIP or GLP-1 receptors. Activation via the glucagon receptor by Retatrutide acetate leads to significant weight reduction and increased energy expenditure. Retatrutide acetate can be utilized in research related to obesity.


    Product Name Retatrutide
    CAS No. 2381089-83-2
    Purity 99%
    Appearance White powder
    Application Healthcare


    Shop Semaglutide Raw Material-Detailed Image 1


      Company Profile 


    Horwats Biotech ,Jiangsu Horwats Biopharmaceutical Co., Ltd., headquartered in Suqian, Jiangsu Province, China, is a comprehensive high-tech enterprise integrating R&D and sales. With strong foundations in synthetic biology, protein purification technology, and fermentation engineering, we are committed to producing high-purity natural active ingredients and pharma-grade raw materials 503A and 503B Compounding Pharmacy.

    Backed by the scientific resources of Jiangnan University and supported by strategic partnerships with Nanjing Horwats Biotech Co., Ltd. and Nantong Juke Biotech Co., Ltd., Horwats Biotech continues to innovate and expand its influence across the pharmaceutical, nutraceutical, and wellness industries.


    Shop Semaglutide Raw Material-Detailed Image 2

    Shop Semaglutide Raw Material-Detailed Image 3 Shop Semaglutide Raw Material-Detailed Image 4

    ECHEMI Editorial Reference

    Semaglutide (CAS: 910463‑68‑2) is a synthetic lipid‑modified peptide analogue, consisting of a 31‑amino‑acid backbone with a covalently attached C18 fatty di‑acid side‑chain via a hydrophilic spacer. It shares 94% amino‑acid sequence homology with native human GLP‑1 peptide. The substance appears as white to almost white hygroscopic powder, with molecular formula C₁₈₇H₂₉₁N₄₅O₅₉ and molecular weight of 4113.58 g/mol. Structural modifications grant it resistance against DPP‑4 enzymatic degradation and enable reversible binding to serum albumin, contributing to its extended in‑vivo half‑life property.

    Certificates

    Basic Info
    Product Name:

    Semaglutide

    Other Name:

    Sermaglutide;Semaglutide impurity;Sermaglutide USP/EP/BP;semaglutide;Sermaglutide CAS 910463 68 2;Semaglutide (H-7894.0001);semgalutide;Semaglutide

    CAS No.:

    910463-68-2

    Molecular Formula:

    C187H291N45O59

    InChIKeys:

    DLSWIYLPEUIQAV-CCUURXOWSA-N

    Molecular Weight:

    4113.57754

    Exact Mass:

    4113.122087 g/mol

    EC Number:

    203-405-2

    Color/Form:

    White to off-white

    Characteristics
    PSA:

    1650 Ų

    XLogP3:

    5.44520

    Critical Temperature & Pressure:

    Store at -20°C

    Research
    Class:

    GLP-1R agonist

    Status:

    FDA-approved (Ozempic / Wegovy / Rybelsus)

    Mechanism:

    Long-acting, selective glucagon-like peptide-1 (GLP-1) receptor agonist with 94% sequence homology to human GLP-1. Engineered for extended half-life (~1 week) via albumin binding (fatty acid acylation at Lys26) and resistance to DPP-4 degradation (Aib substitution at position 8). Promotes insulin secretion, inhibits glucagon release, delays gastric emptying, and reduces appetite via central nervous system GLP-1R activation.

    Activity note:

    Potent, selective GLP-1R agonist. Reported binding affinity Ki = 0.38 ± 0.06 nM. Semaglutide is a human GLP-1 analog with structural modifications for albumin binding (C18 fatty diacid at Lys26) and enzymatic stability (Aib8 substitution).

    Source:

    Lau J, et al. J Med Chem. 2015;58(18):7370-7380. Wilding JPH, et al. N Engl J Med. 2021;384(11):989-1002.DOI

    Clinical Development:

    NCT03548935; NCT03552757; NCT01720446; NCT02692716

    FDA:

    Ozempic, Wegovy, Rybelsus (approved 2017-12-05)

    References
    ChEMBL:

    CHEMBL2108724

    DrugBank:

    DB13928

    KEGG DRUG:

    D10025

    PubChem:

    PubChem

    Disclaimer:

    Semaglutide is approved as a prescription medicine (Ozempic, Wegovy, Rybelsus) in certain jurisdictions. This listing is for industrial and laboratory research use only. Research-chemical listings on B2B marketplaces are not interchangeable with approved medicines. Confirm CAS, specification, and regulatory pathway with the seller. It is not medical advice, a clinical recommendation, or an approved therapy description.

    Hazard Identification

    Classification of the substance or mixture

    Reproductive toxicity, Category 2

    GHS label elements, including precautionary statements

    Pictogram(s)
    Signal word

    Warning

    Hazard statement(s)

    H361 Suspected of damaging fertility or the unborn child

    Precautionary statement(s)
    Prevention

    P203 Obtain, read and follow all safety instructions before use.

    P280 Wear protective gloves/protective clothing/eye protection/face protection/hearing protection/...

    Response

    P318 IF exposed or concerned, get medical advice.

    Storage

    P405 Store locked up.

    Disposal

    P501 Dispose of contents/container to an appropriate treatment and disposal facility in accordance with applicable laws and regulations, and product characteristics at time of disposal.

    Other hazards which do not result in classification

    no data available

    Handling and Storage

    Precautions for safe handling

    Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.

    Conditions for safe storage, including any incompatibilities

    Store the container tightly closed in a dry, cool and well-ventilated place. Store apart from foodstuff containers or incompatible materials.

  • Seller Information
    Business Type:

    Trader

    Main Products:

    Vitamin K2,NAD+,Semaglutide,Tirzepatide,Sodium Glutathione

    Location:

    C4, Lailong Functional Polymer Materials Industrial Park, Lailong Town, Suyu District, Suqian City, Jiangsu Province

    Total Employees:

    51-100

    Year of Establishment:

    2024

    Horwats Biotech ,Jiangsu Horwats Biopharmaceutical Co., Ltd., headquartered in Suqian, Jiangsu Province, China, is a comprehensive high-tech enterprise integrating R&D and sales. With strong foundations in synthetic biology, protein purification technology, and fermentation engineering, we are committed to producing high-purity natural active ingredients and pharma-grade raw materials 503A and 503B Compounding Pharmacy.

    Backed by the scientific resources of Jiangnan University and supported by strategic partnerships with Nanjing Horwats Biotech Co., Ltd. and Nantong Juke Biotech Co., Ltd., Horwats Biotech continues to innovate and expand its influence across the pharmaceutical, nutraceutical, and wellness industries.


  • Inquiry History
    423 Inquiries
    Country Product Purchase Quantity Date Posted
    Belgium

    Semaglutide

    1 MT Oct 19, 2026
    Chile

    Semaglutide

    10 MG Oct 16, 2026
    Slovakia

    semaglutide

    10 MG Oct 15, 2026
    Germany

    Semaglutide

    1 G Oct 14, 2026
    South Africa

    Semaglutide

    10 MT Oct 11, 2026
    United States

    Semaglutide

    1000 MT Oct 6, 2026
    United States

    Semaglutide

    10 MT Sep 30, 2026
    United States

    Semaglutide

    1000 KG Sep 30, 2026
    United States

    Semaglutide

    30 MG Sep 28, 2026
    United States

    Semaglutide

    10 MT Sep 25, 2026
    Philippines

    Semaglutide

    10 MG Sep 20, 2026
    India

    Semaglutide

    10 MG Sep 18, 2026
    United Kingdom

    Semaglutide - Reta - Tirz

    100 MG Sep 17, 2026
    United Kingdom

    Semaglutide

    10 G Sep 17, 2026
    United Kingdom

    Retatruide

    1 MT Sep 15, 2026
    United Kingdom

    IGF-1 LR3

    10 MT Aug 28, 2026
    Paraguay

    Semaglutide Freeze-dried Vial

    1 KG Aug 27, 2026
    United States

    Semaglutide

    2 MT Aug 25, 2026
    United States

    Semaglutide

    1 MT Aug 24, 2026
    United States

    Ghk-cu

    20 MT Aug 21, 2026
    Post an enquiry for this product
pic ×

Scan the QR Code to Share

All products displayed on this website are only for non-medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.

According to relevant laws and regulations and the regulations of this website, units or individuals who purchase hazardous materials should obtain valid qualifications and qualification conditions.

The information shown above is provided by the enterprise itself, and the authenticity, accuracy and legitimacy of the content are the responsibility of the publishing company. ECHEMI does not bear any guarantee responsibility for this. Please be aware that risks in internet transactions objectively exist.

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.